

**INPIXON AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(In thousands, except number of shares and par value data)

	As of	
	March 31, 2021	December 31, 2020
<b>ASSETS</b>		
<b>Current Assets</b>		
Cash and cash equivalents	\$ 46,273	\$ 17,996
Accounts receivable, net	1,240	1,739
Notes and other receivables	160	152
Inventory	1,492	1,243
Short-term investments	50,057	7,998
Prepaid assets and other current assets	1,222	1,197
<b>Total Current Assets</b>	<b>100,444</b>	<b>30,325</b>
Property and equipment, net	1,438	1,445
Operating lease right-of-use asset, net	1,948	2,077
Software development costs, net	1,769	1,721
Long-term investments	2,500	2,500
Intangible assets, net	14,199	14,203
Goodwill	6,370	6,588
Other assets	160	152
<b>Total Assets</b>	<b>\$ 128,828</b>	<b>\$ 59,011</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>Current Liabilities</b>		
Accounts payable	\$ 1,377	\$ 908
Accrued liabilities	3,131	2,739
Operating lease obligation, current	637	647
Deferred revenue	1,667	1,922
Short-term debt	4,251	5,401
Acquisition liability	500	500
<b>Total Current Liabilities</b>	<b>11,563</b>	<b>12,117</b>
<b>Long Term Liabilities</b>		
Operating lease obligations, noncurrent	1,339	1,457
Other liabilities, noncurrent	7	7
Acquisition liability, noncurrent	--	750
<b>Total Liabilities</b>	<b>12,909</b>	<b>14,331</b>
<b>Commitments and Contingencies</b>		
	--	--
<b>Stockholders' Equity</b>		
Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued, and 1 outstanding as of March 31, 2021 and December 31, 2020, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued, and 126 outstanding as of March 31, 2021 and December 31, 2020, respectively.	--	--
Common Stock - \$0.001 par value; 250,000,000 shares authorized; 101,382,448 and 53,178,462 issued and 101,382,447 and 53,178,461 outstanding as of March 31, 2021 and December 31, 2020, respectively.	102	53
Additional paid-in capital	310,013	225,613
Treasury stock, at cost, 1 share	(695)	(695)
Accumulated other comprehensive (loss)/income	(11)	660
Accumulated deficit	(193,549)	(180,992)
Stockholders' Equity Attributable to Inpixon	<b>115,860</b>	<b>44,639</b>
Non-controlling interest	59	41
<b>Total Stockholders' Equity</b>	<b>115,919</b>	<b>44,680</b>
<b>Total Liabilities and Stockholders' Equity</b>	<b>\$ 128,828</b>	<b>\$ 59,011</b>

**INPIXON AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**  
(In thousands, except per share data)

	For the Years Ended	
	March 31,	
	2021	2020
<b>Revenues</b>	\$ 2,954	\$ 1,804
<b>Cost of Revenues</b>	884	510
<b>Gross Profit</b>	2,070	1,294
<b>Operating Expenses</b>		
Research and development	2,708	1,334
Sales and marketing	1,639	691
General and administrative	9,171	3,791
Acquisition related costs	470	28
Amortization of intangibles	502	1,016
<b>Total Operating Expenses</b>	14,490	6,860
<b>Loss from Operations</b>	(12,420)	(5,566)
<b>Other Income (Expense)</b>		
Interest expense, net	(349)	(621)
Loss on exchange of debt for equity	(30)	(86)
Provision for valuation allowance on related party loan - held for sale	(117)	--
Other income	386	18
<b>Total Other Expense</b>	(110)	(689)
<b>Net Loss, before tax</b>	(12,530)	(6,255)
Income tax (provision) benefit	(9)	87
<b>Net Loss</b>	(12,539)	(6,168)
<b>Net Income (loss) Attributable to Non-controlling Interest</b>	18	(10)
<b>Net Loss Attributable to Stockholders of Inpixon</b>	\$ (12,557)	\$ (6,158)
<b>Net Loss Per Share - Basic and Diluted</b>	\$ (0.16)	\$ (1.22)
<b>Weighted Average Shares Outstanding</b>		
Basic and Diluted	78,942,697	5,038,515
<b>Comprehensive Loss</b>		
Net Loss	\$ (12,539)	\$ (6,168)
Unrealized foreign exchange loss from cumulative translation adjustments	(671)	(613)
<b>Comprehensive Loss</b>	\$ (13,210)	\$ (6,781)

**INPIXON AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(In thousands)

	For the Three Months Ended	
	March 31,	
	2021	2020
<b>Cash Flows Used In Operating Activities</b>		
Net loss	\$ (12,539)	\$ (6,168)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	293	210
Amortization of intangible assets	650	1,016
Amortization of right of use asset	181	157
Stock based compensation	5,096	399
Loss on exchange of debt for equity	30	86
Amortization of debt discount	224	868
Accrued interest income, related party	--	(16)
Related party note, gain on foreign currency transaction	(363)	--
Provision for the valuation allowance - held for sale loan	117	--
Income tax expense (benefit)	9	(87)
Other	--	29
Changes in operating assets and liabilities:		
Accounts receivable and other receivables	426	(416)
Inventory	(279)	29
Prepaid expenses and other current assets	135	65
Other assets	(227)	(16)
Accounts payable	480	(568)
Accrued liabilities	421	(113)
Deferred revenue	(235)	31
Operating lease obligation	(176)	(156)
Other liabilities	96	115
Total Adjustments	6,878	1,633
<b>Net Cash Used in Operating Activities</b>	(5,661)	(4,535)
<b>Cash Flows Used in Investing Activities</b>		
Purchase of property and equipment	(109)	(16)
Capitalized software	(253)	(193)
Investment in short term investment	(42,059)	--
Purchase of the Systat Licensing Agreement	(900)	--
<b>Net Cash Flows Used in Investing Activities</b>	(43,321)	(209)
<b>Cash Flows From Financing Activities</b>		
Net repayments to bank facility	--	(150)
Net proceeds from issuance of common stock and warrants	77,853	1,252
Net repayments of notes payable	--	1
Loans to related party	(117)	(184)
Repayments from related party	--	185
Net proceeds from promissory notes	--	5,000
Repayment of acquisition liability to Locality shareholders	(467)	--

<b>Net Cash Provided By Financing Activities</b>	77,269	6,104
<b>Effect of Foreign Exchange Rate on Changes on Cash</b>	(10)	(27)
<b>Net Increase in Cash, Cash Equivalents and Restricted Cash</b>	28,277	1,333
Cash, Cash Equivalents and Restricted Cash - Beginning of period	<u>17,996</u>	<u>4,849</u>
Cash, Cash Equivalents and Restricted Cash - End of period	<u>\$ 46,273</u>	<u>\$ 6,182</u>

## Reconciliation of Non-GAAP Financial Measures:

(In thousands)	For the Three Months Ended	
	March 31,	
	2021	2020
Net loss attributable to common stockholders	\$ (12,557)	\$ (6,158)
Adjustments:		
Non-recurring one-time charges:		
Loss on exchange of debt for equity	30	86
Provision for valuation allowance on held for sale loan	117	--
Professional service fees	349	--
Acquisition transaction/financing costs	470	28
Unrealized gain/loss on note	(363)	--
Stock-based compensation – compensation and related benefits	5,096	399
Interest expense, net	349	621
Income tax provision (benefit)	9	(87)
Depreciation and amortization	943	1,226
Adjusted EBITDA	\$ (5,557)	\$ (3,885)

(In thousands, except share data)	For the Three Months Ended	
	March 31,	
	2021	2020
Net loss attributable to common stockholders	\$ (12,557)	\$ (6,158)
Adjustments:		
Non-recurring one-time charges:		
Loss on exchange of debt for equity	30	86
Provision for valuation allowance on held for sale loan	117	--
Professional service fees	349	--
Acquisition transaction/financing costs	470	28
Unrealized gain/loss on note	(363)	--
Stock-based compensation – compensation and related benefits	5,096	399
Amortization of intangibles	650	1,016
Proforma non-GAAP net loss	\$ (6,208)	\$ (4,629)
Proforma non-GAAP net loss per basic and diluted common share	\$ (0.08)	\$ (0.92)
Weighted average basic and diluted common shares outstanding	78,942,697	5,038,515